Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), counseling women with implants

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon peripheral T cell lymphoma arising around textured-surface breast implants placed for either reconstructive or cosmetic indications. The association of breast implants with a cancer of the immune system has created understandable concern among patients, plastic surgeons, and oncologists.

​

 https://news.v.daum.net/v/20190804203006294

'희귀암 유발' 유방 보형물 회수..수술한 2만 명은?

COUNSELING WOMEN WITH IMPLANTS

​

A safety communication from the US Food and Drug Administration (FDA) cautioned women with breast implants about BIA-ALCL, and included information regarding clinical presentation, prognosis, and treatment options, which increased public and physician awareness of this entity. The initial warning in 2011 was updated in 2019 to acknowledge the awareness of 457 reports of BIA-ALCL, including the deaths of 9 patients that may be attributable to BIA-ALCL, through September 2018. Based on the available data, we agree with the following FDA recommendations for counseling women with implants :

​

BIA-ALCL은 흔하지는 않지만, 유방 보형물을 가진 여성의 질감이 있는 표면 유방 보형물에 인접한 캡슐에서 BIA-ALCL 발병 위험이 작지만 증가 했습니다.

●Although BIA-ALCL is uncommon, women with breast implants have a small but increased risk of developing BIA-ALCL in the capsule adjacent to a textured-surface breast implant.

​

BIA-ALCL이 발생했을 때는 late onset, persistent seroma에 대해 implant revision operations을 받는 환자에서 가장 자주 확인되었습니다. 그러나 일부 경우에는 capsular contracture 또는 breast implant에 인접한 종괴로 내원합니다.

●When BIA-ALCL occurs, it is most frequently identified in patients undergoing implant revision operations for late onset, persistent seroma. However, in some cases, patients present with capsular contracture or masses adjacent to the breast implant.

​

유방 보형물을 가진 여성은 정기적인 자가 유방 검사를 실시하고 어떤 변화를 발견하면 즉시 의료 제공자에게 연락해야 합니다.

●Women with breast implants should perform regular self-breast exams and contact their health care provider promptly if they notice any changes.

​

가족력이 있는 암에 걸릴 가능성이 있는 경우조차도 증상이 없는 유방 보형물을 가진 여성에서는 선별적 또는 예방적 임플란트 제거를 권고하지 않습니다.

●Screening or prophylactic implant removal is NOT recommended for women with breast implants who are asymptomatic, even for those with a familial susceptibility to cancer.

​

REF. UpToDate 2019.08.04